Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 6/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3952472 | 0.91 | CNR2 (0.34) | CNR2CNR1LMNAGAAMAPT | |
| SCHEMBL4163225 | 0.91 | DYRK1A (0.36) | CNR2CNR1LMNAGAAMAPT | |
| SCHEMBL3952475 | 0.89 | MAPT (0.34) | CNR2LMNAGAAMAPTHPGD | |
| SCHEMBL3950042 | 0.89 | LMNA (0.33) | CNR2LMNAGAAMAPTHPGD | |
| SCHEMBL3949297 | 0.88 | CNR2 (0.33) | CNR2CNR1LMNAGAAMAPT | |
| SCHEMBL4164475 | 0.88 | OGA (0.36) | CNR2CNR1LMNAGAAMAPT | |
| SCHEMBL3947866 | 0.88 | CNR1 (0.42) | CNR2CNR1LMNAGAAMAPT | |
| SCHEMBL4157788 | 0.88 | PIK3CG (0.40) | CNR2CNR1LMNAGAAMAPT | |
| SCHEMBL4152458 | 0.87 | SLC22A12 (0.36) | CNR2CNR1LMNAGAAMAPT | |
| SCHEMBL3955271 | 0.87 | DYRK1A (0.41) | CNR1LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093474-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | GRAUERT MATTHIAS | 2009-04-09 | — | — | US | disclosed |
| US-20090093474-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | GRAUERT MATTHIAS | 2009-04-09 | — | — | US | disclosed |
| US-20090093474-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | GRAUERT MATTHIAS | 2009-04-09 | — | — | US | disclosed |
| EP-2018387-A1 | THIAZOLYLDIHYDROINDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007115933-A1 | THIAZOLYLDIHYDROINDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007115933-A1 | THIAZOLYLDIHYDROINDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| US-20070238718-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238718-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238718-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093474-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | CYP3A43, CYP3A5, UGT1A3 | CLK1 1306/4885CNR2 1990/4885CNR1 2170/4885 |
| US-20070238718-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | CYP3A43, CYP3A5, UGT1A3 | CLK1 1306/4885CNR2 1990/4885CNR1 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.